{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T23:38:24Z","timestamp":1789169904753,"version":"build-2803163510"},"reference-count":69,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2008,3]]},"DOI":"10.1097\/ppo.0b013e31816a6058","type":"journal-article","created":{"date-parts":[[2008,5,4]],"date-time":"2008-05-04T04:06:20Z","timestamp":1209873980000},"page":"123-127","source":"Crossref","is-referenced-by-count":32,"title":["Systemic Therapy for Hepatocellular Carcinoma"],"prefix":"10.1097","volume":"14","author":[{"given":"Melanie B.","family":"Thomas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-9-20210203","doi-asserted-by":"crossref","first-page":"10","DOI":"10.3322\/canjclin.55.1.10","article-title":"Cancer statistics, 2005.","volume":"55","author":"Jemal","year":"2005","journal-title":"CA Cancer J Clin"},{"key":"R2-9-20210203","doi-asserted-by":"crossref","first-page":"8","DOI":"10.3322\/canjclin.54.1.8","article-title":"Cancer statistics, 2004.","volume":"54","author":"Jemal","year":"2004","journal-title":"CA Cancer J Clin"},{"key":"R3-9-20210203","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1007\/s10354-006-0316-3","article-title":"Hepatocellular carcinoma\u2014rising incidence, changing therapeutic strategies.","volume":"156","author":"Muller","year":"2006","journal-title":"Wien Med Wochenschr"},{"key":"R4-9-20210203","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1159\/000087267","article-title":"Viral etiology of hepatocellular carcinoma and HCV genotypes in Taiwan.","volume":"49","author":"Lee","year":"2006","journal-title":"Intervirology"},{"key":"R5-9-20210203","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.cgh.2005.12.007","article-title":"The association between diabetes and hepatocellular carcinoma: a systematic review of epidemiologic evidence.","volume":"4","author":"El-Serag","year":"2006","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R6-9-20210203","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1055\/s-2006-939752","article-title":"Hepatitis B virus-related cirrhosis: natural history and treatment.","volume":"26","author":"Chu","year":"2006","journal-title":"Semin Liver Dis"},{"key":"R7-9-20210203","first-page":"291","article-title":"Steatosis and hepatocellular carcinoma risk.","volume":"9","author":"Smedile","year":"2005","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"R8-9-20210203","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1136\/gut.2004.048124","article-title":"Prognostic factors for survival in patients with early-intermediate hepatocellular carcinoma undergoing non-surgical therapy: comparison of Okuda, CLIP, and BCLC staging systems in a single Italian centre.","volume":"54","author":"Grieco","year":"2005","journal-title":"Gut"},{"key":"R9-9-20210203","first-page":"45","article-title":"Is the prevalence of cryptogenic hepatocellular carcinoma increasing in Korea?","volume":"45","author":"Oh","year":"2005","journal-title":"Korean J Gastroenterol"},{"key":"R10-9-20210203","first-page":"1","article-title":"NIH Consensus Statement on Management of Hepatitis C: 2002.","volume":"19","year":"2002"},{"key":"R11-9-20210203","doi-asserted-by":"crossref","first-page":"S27","DOI":"10.1053\/j.gastro.2004.09.013","article-title":"Hepatocellular carcinoma: recent trends in the United States.","volume":"127","author":"El-Serag","year":"2004","journal-title":"Gastroenterology"},{"key":"R12-9-20210203","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1097\/00000658-199304000-00009","article-title":"Liver resection for hepatocellular carcinoma: results of 229 consecutive patients during 11 years.","volume":"217","author":"Nagasue","year":"1993","journal-title":"Ann Surg"},{"key":"R13-9-20210203","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1002\/bjs.1800830142","article-title":"Repeat hepatectomy for recurrent hepatocellular carcinoma.","volume":"83","author":"Nagasue","year":"1996","journal-title":"Br J Surg"},{"key":"R14-9-20210203","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1097\/00000658-199901000-00011","article-title":"Prognostic factors after hepatic resection for hepatocellular carcinoma associated with Child-Turcotte class B and C cirrhosis.","volume":"229","author":"Nagasue","year":"1999","journal-title":"Ann Surg"},{"key":"R15-9-20210203","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1023\/A:1008285123736","article-title":"Treatment of hepatocellular carcinoma: a systematic review of randomized controlled trials.","volume":"8","author":"Simonetti","year":"1997","journal-title":"Ann Oncol"},{"key":"R16-9-20210203","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1093\/jnci\/dji315","article-title":"A randomized phase III study of Adriamycin versus cisplatin\/interferon \u03b1-2b\/Adriamycin\/fluorouracil (PIAF) combination chemotherapy for unresectable hepatocellular carcinoma.","volume":"97","author":"Yeo","year":"2005","journal-title":"J Natl Cancer Inst"},{"key":"R17-9-20210203","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1007\/s002800050982","article-title":"A multi-centre randomized phase II study of nolatrexed versus Adriamycin in treatment of Chinese patients with advanced hepatocellular carcinoma.","volume":"44","author":"Mok","year":"1999","journal-title":"Cancer Chemother Pharmacol"},{"issue":"16 suppl","key":"R18-9-20210203","doi-asserted-by":"crossref","first-page":"4035","DOI":"10.1200\/jco.2005.23.16_suppl.4035","article-title":"Results of a phase 2\/3 open-label, randomized trial of T138067 versus Adriamycin (DOX) in chemotherapy-naive, unresectable hepatocellular carcinoma (HCC).","volume":"23","author":"Posey","year":"2005","journal-title":"J Clin Oncol"},{"key":"R19-9-20210203","doi-asserted-by":"crossref","first-page":"3069","DOI":"10.1200\/JCO.2006.08.4046","article-title":"Phase III randomized controlled trial comparing the survival of patients with unresectable hepatocellular carcinoma treated with nolatrexed or Adriamycin.","volume":"25","author":"Gish","year":"2007","journal-title":"J Clin Oncol"},{"key":"R20-9-20210203","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1002\/cncr.20821","article-title":"Thalidomide in the treatment of patients with hepatocellular carcinoma: a phase II trial.","volume":"103","author":"Patt","year":"2005","journal-title":"Cancer"},{"issue":"18 suppl","key":"R21-9-20210203","doi-asserted-by":"crossref","first-page":"4585","DOI":"10.1200\/jco.2007.25.18_suppl.4585","article-title":"A phase II study of pegylated liposomal doxorubicin (PLD) and gemcitabine (G) in the treatment of hepatocellular carcinoma (HCC) not suitable for loco-regional therapy.","volume":"25","author":"Pastorelli","year":"2007","journal-title":"J Clin Oncol"},{"issue":"suppl 5","key":"R22-9-20210203","doi-asserted-by":"crossref","first-page":"v153","DOI":"10.1093\/annonc\/mdj972","article-title":"Gemcitabine and liposomal Adriamycin in biliary and hepatic carcinoma (HCC) chemotherapy: preliminary results and review of the literature.","volume":"17","author":"Pastorelli","year":"2006","journal-title":"Ann Oncol"},{"issue":"18 suppl","key":"R23-9-20210203","doi-asserted-by":"crossref","first-page":"LBA1","DOI":"10.1200\/jco.2007.25.18_suppl.lba1","article-title":"Randomized phase III trial of sorafenib versus placebo with advanced hepatocellular carcinoma (HCC).","volume":"25","author":"Llovet","year":"2007","journal-title":"J Clin Oncol"},{"key":"R24-9-20210203","doi-asserted-by":"crossref","first-page":"4293","DOI":"10.1200\/JCO.2005.01.3441","article-title":"Phase II study of sorafenib in patients with advanced hepatocellular carcinoma.","volume":"24","author":"Abou-Alfa","year":"2006","journal-title":"J Clin Oncol"},{"issue":"14 suppl","key":"R25-9-20210203","doi-asserted-by":"crossref","first-page":"4025","DOI":"10.1200\/jco.2004.22.90140.4025","article-title":"Phase II trial of erlotinib (OSI-774) in patients with hepatocellular or biliary cancer.","volume":"22","author":"Philip","year":"2004","journal-title":"J Clin Oncol"},{"key":"R26-9-20210203","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1002\/cncr.22886","article-title":"Phase 2 study of erlotinib in patients with unresectable hepatocellular carcinoma.","volume":"110","author":"Thomas","year":"2007","journal-title":"Cancer"},{"issue":"18 suppl","key":"R27-9-20210203","doi-asserted-by":"crossref","first-page":"4567","DOI":"10.1200\/jco.2007.25.18_suppl.4567","article-title":"The combination of bevacizumab (B) and erlotinib (E) shows significant biological activity in patients with advanced hepatocellular carcinoma (HCC).","volume":"25","author":"Thomas","year":"2007","journal-title":"J Clin Oncol"},{"key":"R28-9-20210203","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1002\/cncr.22829","article-title":"Phase 2 study of cetuximab in patients with advanced hepatocellular carcinoma.","volume":"110","author":"Zhu","year":"2007","journal-title":"Cancer"},{"issue":"18 suppl","key":"R29-9-20210203","doi-asserted-by":"crossref","first-page":"4143","DOI":"10.1200\/jco.2006.24.18_suppl.4143","article-title":"Gefitinib in advanced unresectable hepatocellular carcinoma: results from the Eastern Cooperative Oncology Group's Study E1203.","volume":"24","author":"O'Dwyer","year":"2006","journal-title":"J Clin Oncol"},{"issue":"18 suppl","key":"R30-9-20210203","doi-asserted-by":"crossref","first-page":"4574","DOI":"10.1200\/jco.2007.25.18_suppl.4574","article-title":"Combination of capecitabine and oxaliplatin with bevacizumab in treatment of advanced hepatocellular carcinoma (HCC): a phase II study.","volume":"25","author":"Sun","year":"2007","journal-title":"J Clin Oncol"},{"key":"R31-9-20210203","doi-asserted-by":"crossref","first-page":"1898","DOI":"10.1200\/JCO.2005.04.9130","article-title":"Phase II study of gemcitabine and oxaliplatin in combination with bevacizumab in patients with advanced hepatocellular carcinoma.","volume":"24","author":"Zhu","year":"2006","journal-title":"J Clin Oncol"},{"key":"R33-9-20210203","doi-asserted-by":"crossref","first-page":"2505","DOI":"10.1200\/JCO.2005.03.6723","article-title":"Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma.","volume":"24","author":"Ratain","year":"2006","journal-title":"J Clin Oncol"},{"key":"R34-9-20210203","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/S0378-1119(01)00554-6","article-title":"Atypical multidrug resistance may be associated with catalytically active mutants of human DNA topoisomerase II\u03b1.","volume":"272","author":"Okada","year":"2001","journal-title":"Gene"},{"key":"R35-9-20210203","first-page":"1113","article-title":"Prognostic significance of DNA topoisomerase II\u03b1 expression in human hepatocellular carcinoma.","volume":"22","author":"Watanuki","year":"2002","journal-title":"Anticancer Res"},{"key":"R36-9-20210203","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1309\/AC1M-4TY4-U0TN-EN7T","article-title":"Expression of P-glycoprotein in hepatocellular carcinoma: a determinant of chemotherapy response.","volume":"113","author":"Ng","year":"2000","journal-title":"Am J Clin Pathol"},{"key":"R37-9-20210203","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1146\/annurev.bi.58.070189.001033","article-title":"The biochemistry of P-glycoprotein-mediated multidrug resistance.","volume":"58","author":"Endicott","year":"1989","journal-title":"Annu Rev Biochem"},{"key":"R38-9-20210203","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1111\/j.1440-1746.1998.tb00709.x","article-title":"Prognostic significance of pathological and biological factors in hepatocellular carcinoma.","volume":"13","author":"Ng","year":"1998","journal-title":"J Gastroenterol Hepatol"},{"key":"R39-9-20210203","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1093\/jnci\/86.9.700","article-title":"MDR1 gene expression: its effect on drug resistance to Adriamycin in human hepatocellular carcinoma cell lines.","volume":"86","author":"Park","year":"1994","journal-title":"J Natl Cancer Inst"},{"key":"R40-9-20210203","doi-asserted-by":"crossref","first-page":"4877","DOI":"10.1038\/sj.onc.1210266","article-title":"Riboregulator H19 induction of MDR1-associated drug resistance in human hepatocellular carcinoma cells.","volume":"26","author":"Tsang","year":"2007","journal-title":"Oncogene"},{"key":"R41-9-20210203","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1007\/s00280-004-0767-4","article-title":"Mutant p53 expression enhances drug resistance in a hepatocellular carcinoma cell line.","volume":"53","author":"Chan","year":"2004","journal-title":"Cancer Chemother Pharmacol"},{"key":"R42-9-20210203","doi-asserted-by":"crossref","first-page":"2673","DOI":"10.1158\/0008-5472.CAN-05-2290","article-title":"Hepatocyte growth factor and inducible nitric oxide synthase are involved in multidrug resistance-induced angiogenesis in hepatocellular carcinoma cell lines.","volume":"66","author":"Lasagna","year":"2006","journal-title":"Cancer Res"},{"key":"R43-9-20210203","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1016\/S0168-8278(97)80160-2","article-title":"Cytokines and the liver.","volume":"27","author":"Simpson","year":"1997","journal-title":"J Hepatol"},{"key":"R44-9-20210203","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/0950-3528(88)90014-0","article-title":"Liver tumours.","volume":"2","author":"Anthony","year":"1988","journal-title":"Baillieres Clin Gastroenterol"},{"key":"R45-9-20210203","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1136\/mp.51.2.96","article-title":"Hepatocyte proliferation rate is a powerful parameter for predicting hepatocellular carcinoma development in liver cirrhosis.","volume":"51","author":"Borzio","year":"1998","journal-title":"Mol Pathol"},{"key":"R46-9-20210203","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1007\/s005350200149","article-title":"Understanding the hypercarcinogenic state in chronic hepatitis: a clue to the prevention of human hepatocellular carcinoma.","volume":"37","author":"Hino","year":"2002","journal-title":"J Gastroenterol"},{"key":"R47-9-20210203","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1056\/NEJMra021844","article-title":"Drug-induced hepatotoxicity.","volume":"349","author":"Lee","year":"2003","journal-title":"N Engl J Med"},{"key":"R48-9-20210203","doi-asserted-by":"crossref","first-page":"157","DOI":"10.2174\/1389200043489054","article-title":"The effect of liver cirrhosis on the regulation and expression of drug metabolizing enzymes.","volume":"5","author":"Elbekai","year":"2004","journal-title":"Curr Drug Metab"},{"key":"R49-9-20210203","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1002\/hep.510270409","article-title":"Activation of mitogen-activated protein kinases\/extracellular signal-regulated kinases in human hepatocellular carcinoma.","volume":"27","author":"Ito","year":"1998","journal-title":"Hepatology"},{"key":"R50-9-20210203","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1002\/hep.510260615","article-title":"Altered expression of mitogen-activated protein kinases in a rat model of experimental hepatocellular carcinoma.","volume":"26","author":"McKillop","year":"1997","journal-title":"Hepatology"},{"key":"R51-9-20210203","doi-asserted-by":"crossref","first-page":"33","DOI":"10.3748\/wjg.v7.i1.33","article-title":"Effect of phosphorylation of MAPK and Stat3 and expression of c-fos and c-jun proteins on hepatocarcinogenesis and their clinical significance.","volume":"7","author":"Feng","year":"2001","journal-title":"World J Gastroenterol"},{"key":"R52-9-20210203","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1097\/00042737-199912000-00009","article-title":"The role of cAMP-MAPK signalling in the regulation of human hepatocellular carcinoma growth in vitro.","volume":"11","author":"Schmidt","year":"1999","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"R53-9-20210203","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1016\/S0168-8278(99)80354-7","article-title":"Increased activity and expression of MAP kinase in HCC model rats induced by 3\u2032-methyl-4-dimethylamino-azobenzene.","volume":"31","author":"Toyoda","year":"1999","journal-title":"J Hepatol"},{"key":"R54-9-20210203","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1016\/j.yexcr.2006.01.007","article-title":"Insulin-like growth factor-I stimulates H4II rat hepatoma cell proliferation: dominant role of PI-3\u2032K\/Akt signaling.","volume":"312","author":"Alexia","year":"2006","journal-title":"Exp Cell Res"},{"key":"R55-9-20210203","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1158\/0008-5472.CAN-06-3075","article-title":"Concomitant activation of the JAK\/STAT, PI3K\/AKT, and ERK signaling is involved in leptin-mediated promotion of invasion and migration of hepatocellular carcinoma cells.","volume":"67","author":"Saxena","year":"2007","journal-title":"Cancer Res"},{"key":"R56-9-20210203","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1097\/01.tp.0000252780.42104.95","article-title":"Mammalian target of rapamycin pathway activity in hepatocellular carcinomas of patients undergoing liver transplantation.","volume":"83","author":"Sieghart","year":"2007","journal-title":"Transplantation"},{"key":"R57-9-20210203","doi-asserted-by":"crossref","first-page":"8421","DOI":"10.1158\/1078-0432.CCR-04-0941","article-title":"mTOR and P70 S6 kinase expression in primary liver neoplasms.","volume":"10","author":"Sahin","year":"2004","journal-title":"Clin Cancer Res"},{"key":"R58-9-20210203","first-page":"453","article-title":"Expressions of epidermal growth factor family and its receptor in hepatocellular carcinoma cell lines: relationship to cell proliferation.","volume":"14","author":"Hisaka","year":"1999","journal-title":"Int J Oncol"},{"key":"R59-9-20210203","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/0955-2235(91)90008-R","article-title":"Growth factors in liver development, regeneration and carcinogenesis.","volume":"3","author":"Fausto","year":"1991","journal-title":"Prog Growth Factor Res"},{"key":"R60-9-20210203","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1111\/j.1440-1746.2005.04217.x","article-title":"Expression of vascular endothelial growth factor-C in human hepatocellular carcinoma.","volume":"21","author":"Yamaguchi","year":"2006","journal-title":"J Gastroenterol Hepatol"},{"key":"R61-9-20210203","first-page":"725","article-title":"Expression and localization of vascular endothelial growth factor receptors in human hepatocellular carcinoma and non-HCC tissues.","volume":"7","author":"Yamaguchi","year":"2000","journal-title":"Oncol Rep"},{"key":"R62-9-20210203","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1002\/hep.510280111","article-title":"Expression of vascular endothelial growth factor in human hepatocellular carcinoma.","volume":"28","author":"Yamaguchi","year":"1998","journal-title":"Hepatology"},{"key":"R63-9-20210203","first-page":"1299","article-title":"The clinicopathological significance of heparinase and basic fibroblast growth factor expressions in hepatocellular carcinoma.","volume":"7","author":"El-Assal","year":"2001","journal-title":"Clin Cancer Res"},{"key":"R64-9-20210203","first-page":"511","article-title":"Serum vascular endothelial growth factor is a predictor of invasion and metastasis in hepatocellular carcinoma.","volume":"18","author":"Li","year":"1999","journal-title":"J Exp Clin Cancer Res"},{"key":"R65-9-20210203","first-page":"403","article-title":"Correlation of four vascular specific growth factors with carcinogenesis and portal vein tumor thrombus formation in human hepatocellular carcinoma.","volume":"25","author":"Li","year":"2006","journal-title":"J Exp Clin Cancer Res"},{"key":"R66-9-20210203","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1038\/sj.bjc.6603813","article-title":"Mechanisms of adverse effects of anti-VEGF therapy for cancer.","volume":"96","author":"Kamba","year":"2007","journal-title":"Br J Cancer"},{"key":"R67-9-20210203","doi-asserted-by":"crossref","first-page":"167","DOI":"10.3816\/CGC.2005.n.028","article-title":"Sorafenib: scientific rationales for single-agent and combination therapy in clear-cell renal cell carcinoma.","volume":"4","author":"Gollob","year":"2005","journal-title":"Clin Genitourin Cancer"},{"key":"R68-9-20210203","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1101\/sqb.2005.70.044","article-title":"Cancer targets in the Ras pathway.","volume":"70","author":"Rodriguez-Viciana","year":"2005","journal-title":"Cold Spring Harb Symp Quant Biol"},{"key":"R69-9-20210203","first-page":"937","article-title":"Blockade of the vascular endothelial growth factor-receptor 2 pathway inhibits the growth of human renal cell carcinoma, RBM1-IT4, in the kidney but not in the bone of nude mice.","volume":"30","author":"Karashima","year":"2007","journal-title":"Int J Oncol"},{"key":"R70-9-20210203","doi-asserted-by":"crossref","first-page":"3293","DOI":"10.1200\/JCO.2006.06.8080","article-title":"Dynamic contrast-enhanced magnetic resonance imaging as an imaging biomarker.","volume":"24","author":"Hylton","year":"2006","journal-title":"J Clin Oncol"}],"container-title":["The Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/PPO.0b013e31816a6058","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T17:59:42Z","timestamp":1786039182000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00130404-200803000-00009"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,3]]},"references-count":69,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2008]]}},"URL":"https:\/\/doi.org\/10.1097\/ppo.0b013e31816a6058","relation":{},"ISSN":["1528-9117"],"issn-type":[{"value":"1528-9117","type":"print"}],"subject":[],"published":{"date-parts":[[2008,3]]}}}